Intellia Temporarily Pauses Dosing For MAGNITUDE And MAGNITUDE-2 Phase 3 Clinical Trials Of Nex-z
I'm PortAI, I can summarize articles.
Intellia Therapeutics, Inc. (NTLA) has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z due to a report of serious liver issues in a patient. The company is consulting with experts and regulatory authorities while monitoring the situation. Currently, over 650 patients with transthyretin amyloidosis are enrolled in the trials, with more than 450 having been dosed with nex-z.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments